Progress and challenges of human epidermal growth factor receptor 2-low expressing breast cancer

doi:10.3877/cma.j.issn.1674-0793.2024.04.015

Abstract

Abstract:

Breast cancer is the most frequently diagnosed cancer in women, which poses a great threat to women’s health. Human epidermal growth factor receptor 2 (HER-2) is an important target for the treatment of breast cancer, and targeted therapy for HER-2-positive breast cancer has been widely studied. HER-2 low expression was previously classified as negative breast cancer and rarely or could not benefit from traditional anti-HER-2 therapy. However, with the established efficacy of antibody-drug conjugates, HER-2-low expressing breast cancer has become a new subtype for treatment. This article will summarize the definition, clinicopathological features, prognosis and treatment progress of HER-2-low expressing breast cancer.

Key words: Human epidermal growth factor receptor 2, Low expression, Breast neoplasms, Detection criteria, Clinicopathological features, Treatment progress

Xue Li, Mengmeng Han, Xueyuan Feng, Ning Ma. Progress and challenges of human epidermal growth factor receptor 2-low expressing breast cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(04): 308-312.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2024.04.015

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2024/V18/I04/308

References 28

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志, 2021, 31(10): 954-1040.
[3]	《乳腺癌HER2检测指南(2019版)》编写组. 乳腺癌HER2检测指南(2019版)[J]. 中华病理学杂志, 2019, 48(3): 169-175.
[4]	Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20.
[5]	中国抗癌协会国际医疗与交流分会, 中国医师协会肿瘤医师分会乳腺癌学组. 人表皮生长因子受体2低表达乳腺癌临床诊疗共识(2022版)[J]. 中华肿瘤杂志, 2022, 44(12): 1288-1295.
[6]	Guo Y, Xie X, Tang W, et al. Noninvasive identification of HER2-low-positive status by MRI-based deep learning radiomics predicts the disease-free survival of patients with breast cancer[J]. Eur Radiol, 2024, 34(2): 899-913.
[7]	Ramtohul T, Djerroudi L, Lissavalid E, et al. Multiparametric MRI and radiomics for the prediction of HER2-zero, -low, and -positive breast cancers[J]. Radiology, 2023, 308(2): e222646.
[8]	Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape[J]. J Clin Oncol, 2020, 38(17): 1951-1962.
[9]	Schettini F, Chic N, Brasó-Maristany F, et al. Author correction: clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer[J]. NPJ Breast Cancer, 2023, 9(1): 32.
[10]	Zhang G, Ren C, Li C, et al. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status[J]. BMC Med, 2022, 20(1): 142.
[11]	Xu H, Han Y, Wu Y, et al. Clinicopathological characteristics and prognosis of HER2-low early-stage breast cancer: A single-institution experience[J]. Front Oncol, 2022, 12: 906011.
[12]	Won HS, Ahn J, Kim Y, et al. Clinical significance of HER2-low expression in early breast cancer: A nationwide study from the Korean Breast Cancer Society[J]. Breast Cancer Res, 2022, 24(1): 22.
[13]	Li Y, Abudureheiyimu N, Mo H, et al. In real life, low-level HER2 expression may be associated with better outcome in HER2-negative breast cancer: A study of the national cancer center, China[J]. Front Oncol, 2022, 11: 774577.
[14]	Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials[J]. Lancet Oncol, 2021, 22(8): 1151-1161.
[15]	de Moura Leite L, Cesca MG, Tavares MC, et al. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer[J]. Breast Cancer Res Treat, 2021, 190(1): 155-163.
[16]	Gianni L, Lladó A, Bianchi G, et al. Open-label, phase Ⅱ, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer[J]. J Clin Oncol, 2010, 28(7): 1131-1137.
[17]	Press MF, Finn RS, Cameron D, et al. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and Lapatinib efficacy in women with metastatic breast cancer[J]. Clin Cancer Res, 2008, 14(23): 7861-7870.
[18]	Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase Ⅱ study of the antibody drug conjugate Trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER-2)-positive breast cancer after prior HER2-directed therapy[J]. J Clin Oncol, 2011, 29(4): 398-405.
[19]	Krop IE, LoRusso P, Miller KD, et al. A phase Ⅱ study of Trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with Trastuzumab, Lapatinib, an anthracycline, a taxane, and capecitabine[J]. J Clin Oncol, 2012, 30(26): 3234-3241.
[20]	Banerji U, van Herpen CML, Saura C, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: A phase 1 dose-escalation and dose-expansion study[J]. Lancet Oncol, 2019, 20(8): 1124-1135.
[21]	Wang J, Liu Y, Zhang Q, et al. RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer：A pooled analysis of two studies[J]. J Clin Oncol, 2021, 39(15): 1022.
[22]	Schmid P, Cortés J, Marmé F, et al. Sacituzumab govitecan efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer by HER2 immunohistochemistry status in the phase Ⅲ TROPiCS-02 study[J]. Ann Oncol, 2022, 33 (suppl 7): S88–S121.
[23]	Mittendorf EA, Ardavanis A, Symanowski J, et al. Primary analysis of a prospective, randomized, single-blinded phase Ⅱ trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence[J]. Ann Oncol, 2016, 27(7): 1241-1248.
[24]	Clifton GT, Hale D, Vreeland TJ, et al. Results of a randomized phase Ⅱb trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to prevent recurrences in patients with high-risk HER2 low-expressing breast cancer[J]. Clin Cancer Res, 2020, 26(11): 2515-2523.
[25]	Yi M, Wu Y, Niu M, et al. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer[J]. J Immunother Cancer, 2022, 10(12): e005543.
[26]	Wu Y, Zhong R, Ma F. HER2-low breast cancer: novel detections and treatment advances[J]. Crit Rev Oncol Hematol, 2023, 181: 103883.
[27]	Fernandez AI, Liu M, Bellizzi A, et al. Examination of low ERBB2 protein expression in breast cancer tissue[J]. JAMA Oncol, 2022, 8(4): 1-4.
[28]	Lambein K, Van Bockstal M, Vandemaele L, et al. Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance[J]. Am J Clin Pathol, 2013, 140(4): 561-566.

Please choose a citation manager

Content to export